Drug
AB928 clinical trials
Also written AB928 and Etrumadenant.
- studies test it
- 20
- open now
- 3
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the AB928 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
20 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 13
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 7
Arcus Biosciences, Inc. (9) · Hoffmann-La Roche (2) · Memorial Sloan Kettering Cancer Center (1) · M.D. Anderson Cancer Center (1) · Washington University School of Medicine (1) · Gilead Sciences (1) · Weill Medical College of Cornell University (1) · Gulam Manji (1)
Often tested with
Tested in the same studies.
Zimberelimab (10) · Domvanalimab (3) · Bevacizumab (3) · Pemetrexed (2) · Paclitaxel (2) · Atezolizumab (2) · Selicrelumab (2) · Quemliclustat (2)
Studies
Open first, then newest update. How each study uses AB928 is read from its arms, and is right about nine times in ten.
Testing it · 20
- A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.RecruitingPhase 2Weill Medical College of Cornell UniversityNCT05024097Written as Etrumadenant (AB928)
- Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Gulam ManjiNCT06048484Written as Etrumadenant
- Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerRecruitingPhase 2Catherine SpinaNCT05915442Written as Etrumadenant
- A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05886634Written as Etrumadenant
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial CarcinomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05335941Written as Etrumadenant
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerCompletedPhase 2Arcus Biosciences, Inc.NCT04262856Written as Etrumadenant
- Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerActive, not recruitingPhase 2Washington University School of MedicineNCT04791839Written as Etrumadenant
- Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05633667Written as Etrumadenant (ETRUMA)
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT03193190Written as AB928
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.CompletedPhase 1/2Arcus Biosciences, Inc.NCT04660812Written as Etrumadenant
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedPhase 1/2Arcus Biosciences, Inc.NCT04381832Written as Etrumadenant
- Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate CancerTerminatedPhase 2Coherus Biosciences, Inc.NCT05177770Written as etrumadenant
- A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerCompletedPhase 1Arcus Biosciences, Inc.NCT03846310Written as Etrumadenant
- A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of CancerCompletedPhase 1Arcus Biosciences, Inc.NCT05411146Written as [14C]-etrumadenant
- A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult ParticipantsCompletedPhase 1Arcus Biosciences, Inc.NCT05277012Written as Etrumadenant
- A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult ParticipantsCompletedPhase 1Arcus Biosciences, Inc.NCT05154136Written as Etrumadenant
- A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT03629756Written as Etrumadenant
- A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT03720678Written as etrumadenant
- A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck CancersWithdrawnPhase 1Jennifer ChoeNCT04892875Written as Etrumadenant
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedPhase 1/2Hoffmann-La RocheNCT03555149Written as AB928
Given in every arm · 2 — AB928 is usual care beside what is tested
- Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyRecruitingPhase 2David OhNCT03821246Written as Etrumadenant
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT03719326Written as Etrumadenant
Codes
What other systems call AB928 · ClinicalTrials.gg INT018287
- UNII (FDA) W0ZE0NT8IFETRUMADENANTConfirmed FDA, Wikidata
- Wikidata Q66977586AB928Confirmed FDA, Wikidata
- DrugBank DB17506One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W0ZE0NT8IF | ETRUMADENANT | Confirmed FDA, Wikidata |
| Wikidata | Q66977586 | AB928 | Confirmed FDA, Wikidata |
| DrugBank | DB17506 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.